*July 2019* by Dr. C.H. Weaver M.D. for CancerConnect. Tagrissio, Tarceva and other TKI therapy for EGFR + NSCLC continue to evolve and improve survival.Advances in cancer research have highlighted the importance of understanding the specific characteristics of each person’s cancer. These
*July 2019* by Dr. C.H. Weaver M.D. for CancerConnect. BiTE antibodies are showing promise as a potential new treatment option for those of us that have progressed on standard of care treatment. What exactly is a BiTE antibody? BiTE is short
*July 2019* The Oncologist. With the advent of immunotherapy, substantial progress has been made in improving outcomes for patients with advanced cancer. However, not all patients benefit equally from treatment, and confounding immune‐related issues may have an impact. Several
Understand the EGFR mutation in lung cancer through this discussion between Dr. Natasha Leighl of Princess Margaret Hospital in Toronto and patient and advocate Jill Feldmen. LCFA's Hope with Answers' Intro video series provides basic information for those newly
We are very excited to announce that the EGFR Resisters will be holding our first Research Summit in collaboration with CEC Oncology, thanks to an independent educational grant from AstraZeneca. We are currently inviting Young Investigators (Junior Faculty or
*June 2019* written by Ivy Elkins for Lungcancer.net I just saw my 18-year-old son graduate from high school. Although this seemed impossible when I was first diagnosed in 2013, I was here to watch him walk across the stage
*June 2019* Medscape. The latest research indicates immunotherapy followed by osimertinib resulted in serious irAEs (severe immune related adverse events) in some advanced lung cancer patients. Medscape (3/20, Castellino, Subscription Publication) reports a study team “notes that serious iirAEs were
*January 2019* Lung Cancer. This small study from Taiwan was performed to investigate the relationship between PD-L1 expression levels and resistance to EGFR-TKI medications in patients with treatment-naïve advanced EGFR mutant lung adenocarcinoma. (By treatment naïve, these patients had
*March 2019* Overview written by Donald Ox. This article deals with a case study of the latest clinical data of brigatinib + cetuximab combo that has stabilized a triple-mutant EGFR patient with concomitant EGFR-T790M and C797S mutations. Brigatinib, the
*March 2019* This is an overview (written by Donald Ox) of the current EGFR TKIs and acquired resistance leading to the effectiveness of the afatinib + cetuximab combo treatment especially useful for T790M negative patients who developed acquired resistance to
*March 2019* Currently available for research purposes only, the Signatera (RUO) is the first ctDNA (circulating tumor DNA) assay custom-built for treatment monitoring and minimal residual disease (MRD) assessment. The test is being developed by Natera and is not yet
*January 29, 2019* Lungevity, by Juhi Kunde. In 2004, after the discovery of mutations in the EGFR gene in lung cancer, the FDA approved a targeted therapy that increased survival in EGFR-positive NSCLC patients. However, the tumors inevitably became
*January 2019* Harvard Health Publishing, Harvard Medical School, by Stephen Lyons. When Dr. Lecia Sequist was undergoing her training to become a medical oncologist at Massachusetts General Hospital (MGH) in the early 2000s, the treatments available for lung cancer
*January 25, 2019* Targeted Oncology, Tony Berberabe. Patients who continued receiving osimertinib (Tagrisso) after their non–small cell lung cancer (NSCLC) had progressed demonstrated a prolonged benefit beyond the initial progression event, according to a retrospective analysis of 118 patients from
*November 10, 2018* GRACE partnered with Swedish Cancer Institute to present a discussion on Local Therapies for Metastatic Lung Cancer. Videos from the live webcast: Newer Technologies in Radiation; Novel Indications for Local Therapy in Advanced NSCLC; Systemic Therapies
*December 10, 2018, University of Texas M. D. Anderson Cancer Center* Researchers at The University of Texas MD Anderson Cancer Center have identified a link between an enzyme tied to cancer formation and therapy resistance in patients with epidermal growth
June 12 2018. A first of its kind treatment vaccine has moved into a phase I clinical trial for patients with non-small cell lung cancer (NSCLC), under a collaboration agreement between Cancer Research UK and Asterias Biotherapeutics Inc. Cancer
Scientists, physicians and patients collaborate to improve treatment for rare cancer SAN CARLOS, CA (November 14, 2018) — The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology and EGFR Resisters today announced the launch of a new study to create a novel bank of patient derived
*NATURE COMMUNICATIONS | (2018) 9:4655 | DOI: 10.1038/s41467-018-07078-0 | www.nature.com/naturecommunications * The emergence of acquired resistance against targeted drugs remains a major clinical challenge in lung adenocarcinoma patients. In a subgroup of these patients we identified an association between
*November 7, 2018* Janssen Biotech has bought Yuhan’s Lazertinib, a novel clinical-stage therapeutic candidate for the treatment of patients with non-small cell lung cancer (NSCLC). J&J’s pharma arm, Janssen, struck the deal with South Korea-based Yuhan and has agreed
By Donna Fernandez · November 9, 2018. I generally begin November by listing, day by day, that for which I am grateful. Some days, the only thing that really strikes me is that I got up that morning or that the sun is shining.
June 19th Living Room "Resistance to Targeted Therapy" Dr. Colin Blakely will be discussing all the questions about progression in your lung cancer and where to go and what to do. Dr. Blakely will be talking about what is happening in the
*** This article was first posted on www.curetoday.com*** During summer 2015, Teri Kennedy was at a yoga festival in Squaw Valley, California, when she started to wheeze and had trouble breathing. The inhaler her doctor gave her didn’t help.
Do you (or a loved one) have EGFR-positive lung cancer? Your voice matters! By participating in this survey, YOU could help shape EGFR-positive lung cancer treatment development and future research, ensuring that they address what is most important to the EGFR-positive lung cancer community.